Compare ROCK & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROCK | HRMY |
|---|---|---|
| Founded | 1972 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 1993 | 2020 |
| Metric | ROCK | HRMY |
|---|---|---|
| Price | $50.47 | $38.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $51.33 |
| AVG Volume (30 Days) | 314.6K | ★ 734.0K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | 0.13 | ★ 3.17 |
| Revenue | ★ $1,383,811,000.00 | $825,944,000.00 |
| Revenue This Year | N/A | $23.11 |
| Revenue Next Year | $6.98 | $16.15 |
| P/E Ratio | $374.63 | ★ $12.13 |
| Revenue Growth | ★ 23.49 | 21.13 |
| 52 Week Low | $42.86 | $25.52 |
| 52 Week High | $75.08 | $40.93 |
| Indicator | ROCK | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 59.90 |
| Support Level | $48.76 | $37.12 |
| Resistance Level | $51.96 | $39.60 |
| Average True Range (ATR) | 1.52 | 1.31 |
| MACD | 0.40 | -0.32 |
| Stochastic Oscillator | 41.83 | 36.53 |
Gibraltar Industries Inc manufactures and provides products and services for the Renewable energy, Residential, Agtech, and Infrastructure markets. The Renewables Segment is engaged in designing, engineering, manufacturing, and installing solar racking and electrical balance systems. Agtech Segment provides growing and processing solutions including the designing, engineering, manufacturing, full-scope construction, maintenance, and support of greenhouses and indoor growing operations, and botanical extraction systems. It derives key revenue from the Residential segment which offers roof and foundation ventilation products, single point and centralized mail systems electronic package solutions, and Retractable awnings and gutter guards, among other products.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.